Why the study?
Current treatments for Alzheimer's disease provide modest impact on outcomes, and their efficacy across different stages of dementia over time is not fully understood.
Do cholinesterase inhibitors and memantine improve cognitive and functional outcomes in patients with Alzheimer's disease?
Do cholinesterase inhibitors and memantine improve cognitive and functional outcomes in patients with Alzheimer's disease?
Cholinesterase inhibitors and memantine offer modest cognitive and functional stabilization in Alzheimer's disease, with combination therapy being beneficial in moderate to severe stages.
Supports modest stabilization across Alzheimer's stages; leaves open optimal duration, subgroups, and long-term outcomes.
Alzheimer’s disease (AD) is the most common cause of dementia that leads over time to profound disability. Current pharmacological interventions for AD are limited to three cholinesterase inhibitors (donepezil, rivastigmine and galantamine) and the N-Methyl-D-Aspartate (NMDA)-receptor antagonist memantine, both of which provide modest impact on cognitive and functional outcomes. In this study we aimed to evaluate the effect of current treatment for Alzheimer’s disease in different stages of dementia. Cholinesterase inhibitors alone, or in combination with memantine may be beneficial in Alzheimer’s disease depending on stage of AD. There is evidence for stabilization of cognitive function in AD for 2–5 months after the initiation of anti-dementia drugs and the efficacy over time is not fully understand.
No takes yet. Share an insight, caveat, or question.
Delia Sterpu (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: